S-1: CEL-SCI Files $15M Common Stock & Warrant Offering

CEL-SCI Corporation has filed a registration statement for a best-efforts offering of up to 3,440,367 shares of common stock and pre-funded warrants to raise approximately $13.7 million in net proceeds.

Summary

• The company is offering up to 3,440,367 shares of common stock and an equal number of pre-funded warrants.
• The assumed public offering price is $4.36 per share, based on the April 14, 2026, closing price.
• Pre-funded warrants are priced at the public offering price minus $0.0001 and are exercisable at $0.0001 per share.
• The offering is being conducted on a 'best efforts' basis with no minimum offering requirement.
• Estimated net proceeds are approximately $13.7 million, intended for the development of Multikine and general corporate purposes.
• The company has engaged ThinkEquity LLC as the exclusive placement agent.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a high-risk capital raise necessitated by the company's ongoing losses and 'going concern' warning, despite the potential promise of its clinical data.

Positives

• Phase III clinical trial data for Multikine in the target population showed a 73% 5-year survival rate compared to 45% in the control group.
• The hazard ratio for the target population was 0.35, indicating a significant reduction in the risk of death.
• The FDA has indicated that the company may proceed with a confirmatory registration study.
• Multikine demonstrated no significant safety signals or toxicities in clinical trials.
• The company has received orphan drug designation for Multikine for the treatment of squamous cell carcinoma of the head and neck.

Negatives

• The company has incurred significant losses to date and expects continued future losses.
• Management has identified conditions and events that raise substantial doubt about the company's ability to continue as a going concern.
• The company reported material weaknesses in its internal control over financial reporting as of September 30, 2025.
• The offering is on a 'best efforts' basis with no minimum, meaning the company may raise significantly less than the target amount.
• Investors will experience immediate and substantial dilution of approximately $2.21 per share.

Risks

• Heavy dependence on the success of a single product candidate, Multikine.
• No products are currently approved for sale, and there is no guarantee of future regulatory approval.
• Clinical trials are expensive, time-consuming, and subject to significant uncertainty and potential delays.
• The company may need to conduct a bridging study for the PD-L1 assay, which could delay marketing approval.
• The company may be unable to raise sufficient capital to complete its planned confirmatory Phase III study.
• Geopolitical risks, including conflicts in the Middle East, could impact operations and financial condition.

Future Outlook

The company plans to initiate a 212-patient confirmatory Phase III registration study for Multikine in the target population as soon as capital is raised, with full enrollment expected 18-24 months later, followed by a potential request for early approval.

Management Comments

• The company believes Multikine significantly extended life in the target patient population.
• The company believes the confirmatory study has a high likelihood of success based on the large survival benefit already observed.
• The company believes Multikine should be added to the standard of care for the target population if approved.

Industry Context

StockSavvy.ai notes that CEL-SCI is operating in the highly competitive cancer immunotherapy market, which is projected to reach $196.45 billion by 2030. The company's focus on a specific niche (low PD-L1 expression) differentiates it from major checkpoint inhibitors like Keytruda and Opdivo, which typically target high PD-L1 expression.

Comparison to Industry Standards

• Multikine is administered as a neoadjuvant therapy before surgery, unlike many other immunotherapies that are administered post-surgery.
• The company's target population (low PD-L1) is distinct from the high PD-L1 population served by Merck's Keytruda.
• The company's Phase III results in the target population showed a 73% 5-year survival rate, which the company compares favorably to the standard of care.

Corporate Governance

Related Party Transactions

• The company has issued restricted shares to consultants and officers for services, as disclosed in the filing.

Stakeholder Impact

• Existing shareholders will face immediate and substantial dilution.
• Investors in the offering will hold speculative securities with no guarantee of product approval.
• The company's ability to continue as a going concern is dependent on the success of this capital raise.

Next Steps

• Pricing of the offering.
• Closing of the offering.
• Initiation of the 212-patient confirmatory Phase III registration study.
• Selection of a diagnostic partner for the PD-L1 companion diagnostic test.

Key Dates

Recommendation

The stock is highly speculative due to the 'going concern' warning and reliance on a single clinical-stage asset. While the Phase III data is compelling, the dilution from this offering and the significant regulatory hurdles ahead warrant a cautious 'hold' until further progress is made on the confirmatory study.

Keywords

CEL-SCI, CVM, Multikine, Biotechnology, Cancer Immunotherapy, Head and Neck Cancer, Clinical Trials, SEC Filing, S-1, Equity Offering